Skip to main content
Premium Trial:

Request an Annual Quote

Sanger Institute, ABI Collaborating on Cancer Genome Study

NEW YORK (GenomeWeb News) – Researchers from the Wellcome Trust Sanger Institute and Applied Biosystems are collaborating on a sequencing project aimed at garnering a detailed understanding of the genetic variation associated with cancer development, ABI announced today.
 
Under the collaboration, investigators from the UK and the US plan to sequence a cancer genome and normal DNA from cell lines derived from one individual with small cell lung cancer using five ABI SOLiD Systems and deep-shotgun resequencing. The project, which is an extension of the Sanger Institute’s Cancer Genome Project, builds on recently published research revealing structural variation within normal and cancerous cell lines at low coverage.
 
For this project, the team plans to survey both SNPs and structural variations to get deeper coverage and a more comprehensive view of genetic variation in cancer. The team hopes to achieve 20-fold genome coverage of both the cancer genome and normal genome using paired-end reads and inserts of various sizes — up to 10,000 base pairs. To aid sequence assembly, they reportedly plan to use the SOLiD System’s mate-pair analysis.
 
“We anticipate that the SOLiD System’s high-throughput capabilities will allow us to cost-effectively reduce the number of runs needed to achieve the 20-fold coverage we are seeking, and will enable us to identify and recognize single nucleotide polymorphisms and rearrangements more accurately,” Mike Stratton, co-head of the Sanger Institute’s Cancer Genome Project, said in a statement.
 
Preliminary results are expected to be presented at the Biology of Genomes meeting at Cold Spring Harbor Laboratory next week.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.